The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the ...

If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...

Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...

The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump sought to ease concerns that a dismissal of ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its ...

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

Johnson & Johnson on Wednesday reported second quarter results that topped estimates and the company lifted its full-year outlook.

Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...